{"slug":"liraglutide","seoKey":"liraglutide","inn":"liraglutide","displayName":"Liraglutide","codes":["NN2211","NNC 90-1170","NN8022","EX2211"],"synonyms":["liraglutidum","liraglutida","Liraglutid","Arg34Lys26-(N-epsilon-(gamma-Glu(N-alpha-hexadecanoyl)))-GLP-1(7-37)","N26-(Hexadecanoyl-gamma-glutamyl)-(34-arginine)GLP-1-(7-37)-peptide","GLP-1 receptor agonist (substance class, not a trade name)"],"legalClass":"rx","identifiers":{"cas":"204656-20-2","pubchemCid":16134956,"unii":"839I73S42A","inchikey":"YSDQQAXHVYUZIW-QCIJIYAXSA-N","drugbankId":"DB06655","chemblId":"CHEMBL1201866","wikidataQid":"Q2526479","formula":"C172H265N43O51","molecularWeight":3751.2},"approvals":[{"market":"US","status":"approved_rx","date":"2010-01-25","note":"Approved and prescription-only. Two marketing applications cover type 2 diabetes from ten years of age, cardiovascular risk reduction in established cardiovascular disease, and chronic weight management from twelve years of age; a fixed combination with a basal insulin exists as a third application. Generic versions have been approved since December 2024. Unlike the European product information, the US labels carry a boxed warning on thyroid C-cell tumours.","source":"https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022341%22"},{"market":"EU","status":"approved_rx","date":"2009-06-30","note":"Authorised centrally and prescription-only. Two authorisations cover type 2 diabetes from ten years of age and weight management; for weight management the European indication reaches further than the US one and includes children from six years of age. The product information carries no boxed warning, and hypersensitivity is the only contraindication listed.","source":"https://www.ema.europa.eu/en/medicines/human/EPAR/victoza"},{"market":"DE","status":"approved_rx","date":"2009-06-30","note":"Authorised through the centralised EU procedure and prescription-only under the German Medicines Act, dispensed only against a prescription. For weight management, statutory health insurance does not cover it under section 34(1) sentence 7 of the German Social Code, Book V; in the diabetes indication it is reimbursable in principle.","source":"https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda"},{"market":"UK","status":"approved_rx","note":"Authorised and prescription-only, with generic versions on the market alongside the originator. In January 2026 the regulator strengthened the warnings on acute pancreatitis for GLP-1 and dual GLP-1/GIP receptor agonists and named this substance explicitly.","source":"https://www.medicines.org.uk/emc/search?q=liraglutide"},{"market":"AU","status":"approved_rx","date":"2026-05-28","note":"Listed in the Poisons Standard as Schedule 4, prescription only, without any exemption. Date given is the registration of the June 2026 Poisons Standard instrument (F2026L00633), not a first approval; the Australian Register of Therapeutic Goods could not be queried on 10 September 2026, so registration numbers are deliberately absent.","source":"https://www.tga.gov.au/products/unapproved-therapeutic-goods/scheduling-basics/poisons-standard-susmp"},{"market":"CA","status":"approved_rx","date":"2010-05-27","note":"Authorised with drug identification numbers and marketed; classified as prescription and, as a biologic drug, additionally under Schedule D. The fixed combination with a basal insulin has been cancelled post market since 31 December 2025.","source":"https://health-products.canada.ca/api/drug/drugproduct/?lang=en&type=json&id=83627"},{"market":"CH","status":"approved_rx","date":"2009-12-11","note":"Authorised and prescription-only (dispensing category B), classified as a biotechnological medicine. The authorisation covering type 2 diabetes runs until 28 February 2027; a separate weight-management product is not listed in the Swiss register of authorised packs.","source":"https://www.swissmedic.ch/swissmedic/en/home/services/listen_neu.html"}],"devStage":"approved","strongestEvidence":"rct_phase3","wada":{"status":"not_listed","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[{"nct":"NCT01179048","name":"LEADER (cardiovascular outcomes in type 2 diabetes)","phase":"Phase 3","n":9341,"status":"COMPLETED"},{"nct":"NCT01272219","name":"SCALE Obesity and Prediabetes (weight reduction without diabetes; 160-week diabetes-onset extension)","phase":"Phase 3","n":3731,"status":"COMPLETED"},{"nct":"NCT01272232","name":"SCALE Diabetes (weight reduction with type 2 diabetes)","phase":"Phase 3","n":846,"status":"COMPLETED"},{"nct":"NCT00781937","name":"SCALE Maintenance (holding a diet-induced weight loss)","phase":"Phase 3","n":422,"status":"COMPLETED"},{"nct":"NCT02918279","name":"SCALE Teens (adolescents from 12 years)","phase":"Phase 3","n":251,"status":"COMPLETED"},{"nct":"NCT04074161","name":"STEP 8 (head-to-head comparison with semaglutide)","phase":"Phase 3b","n":338,"status":"COMPLETED"},{"nct":"NCT00518882","name":"LEAD-6 (head-to-head comparison with exenatide)","phase":"Phase 3","n":464,"status":"COMPLETED"}],"sameAs":["https://www.wikidata.org/wiki/Q2526479","https://pubchem.ncbi.nlm.nih.gov/compound/16134956","https://go.drugbank.com/drugs/DB06655","https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201866/"],"lastVerified":"2026-09-10","version":"1.0","published":true,"locale":"en","title":"Liraglutide: what the trials show, status and safety","summary":"Liraglutide is a lab-made copy of a natural gut hormone, altered so that it survives in the body for about half a day instead of a few minutes. It has been an approved, prescription-only medicine since 2009, first for type 2 diabetes and later for weight management. In its largest weight trial, adults lost an average of 8.4 kg over 56 weeks, against 2.8 kg on a dummy treatment. In a heart trial in people with diabetes, serious heart events were about 13 percent less common. Its younger relative semaglutide beat it clearly in the one trial that put the two side by side.","updated":"2026-09-10","url":"https://mypep.app/peptides/liraglutide"}